Article
Advances in targeted therapy for melanoma.
Clinical advances in hematology & oncology : H&O - 1 Sept 2010
Friedlander Philip, Hodi F Stephen
Abstract excerpt
Metastatic melanoma remains an aggressive malignancy conferring a very poor prognosis, and standard chemotherapeutic and immunologic treatments have not demonstrated an overall survival benefit. No molecularly targeted therapy is approved for the treatment of advanced melanoma. Melanoma is a molecularly heterogeneous malignancy, and optimal treatment in a given patient is likely to depend on the presence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
